Blueprint Medicines
BPMC
BPMC was delisted on the 17th of July, 2025.
352 hedge funds and large institutions have $6.12B invested in Blueprint Medicines in 2025 Q1 according to their latest regulatory filings, with 61 funds opening new positions, 132 increasing their positions, 116 reducing their positions, and 52 closing their positions.
44% more call options, than puts
Call options by funds: $144M | Put options by funds: $100M
17% more first-time investments, than exits
New positions opened: 61 | Existing positions closed: 52
14% more repeat investments, than reductions
Existing positions increased: 132 | Existing positions reduced: 116
13% more funds holding in top 10
Funds holding in top 10: 8 → 9 (+1)
2.45% more ownership
Funds ownership: 105.71% → 108.16% (+2.4%)
2% more funds holding
Funds holding: 345 → 352 (+7)
4% more capital invested
Capital invested by funds: $5.86B → $6.12B (+$262M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$260M |
| 2 |
JP Morgan Chase
New York
|
+$132M |
| 3 |
SL
Siren LLC
Greenwich,
Connecticut
|
+$70.8M |
| 4 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$59.1M |
| 5 |
B
Braidwell
Stamford,
Connecticut
|
+$42.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$118M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$79.5M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$60.9M |
| 4 |
William Blair Investment Management
Chicago,
Illinois
|
-$50.2M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$25.7M |
BPMC Hedge Fund Activity: Q1 2025 in Review
352 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q1 2025, worth a combined $6.12B — up 4.5% from $5.86B a quarter earlier.
Buyers outnumbered sellers: 61 funds opened new BPMC positions and 52 closed out — a net gain of 9 holders — while 132 added to existing stakes and 116 trimmed.
The largest buyer was Avoro Capital Advisors, adding an estimated $260M. The largest seller was Wellington Management Group, cutting an estimated $118M.
- 352 institutional investors held Blueprint Medicines (BPMC) as of Q1 2025, up from 345 in Q4 2024.
- Funds reported $6.12B of Blueprint Medicines stock for Q1 2025, up 4.5% quarter-over-quarter.
- 61 funds opened new Blueprint Medicines positions in Q1 2025 and 52 closed out, a net change of +9 holders.
- The largest Blueprint Medicines buyer in Q1 2025 was Avoro Capital Advisors, an estimated $260M added.
- The largest Blueprint Medicines seller in Q1 2025 was Wellington Management Group, an estimated $118M sold.
Based on aggregated 13F filings for Q1 2025.